BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 22, Issue 28
This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (13096)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.
Item 
Count 
PDF2309
WORD362
HTML8167
Figures (1-1)172
Tables (1-3)130
 Sum=11140
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse856
Download1100
 Sum=1956
Jul 28, 2016 (publication date) through May 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, Ip B, So J, Lai J, Ng J, Tam TH. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22(28): 6484-6500 [PMID: 27605883 DOI: 10.3748/wjg.v22.i28.6484]
URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6484.htm
Number Citing Articles
1
Marco Picardi, Roberta Della Pepa, Claudia Giordano, Irene Zacheo, Novella Pugliese, Chiara Mortaruolo, Fabio Trastulli, Antonio Giordano, Mariano Lucignano, Maria Di Perna, Marta Raimondo, Claudia Salvatore, Fabrizio Pane. Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood 2019; 133(5): 498 doi: 10.1182/blood-2018-10-878892
2
Jeffrey J. Bruno, Frank P. Tverdek. Oncologic Critical Care. 2019; : 1 doi: 10.1007/978-3-319-74698-2_27-1
3
Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura, Manabu Sugita. Current perspectives of viral hepatitis. World Journal of Gastroenterology 2024; 30(18): 2402-2417 doi: 10.3748/wjg.v30.i18.2402
4
Murali Janakiram, Sakshi Jasra, David Aboulafia. Effect of Hepatitis B and C Infection on Recruitment for Cancer Clinical Trials. Journal of Clinical Oncology 2018; 36(10): 1047 doi: 10.1200/JCO.2017.76.9307
5
Nobuhiko Yamauchi, Dai Maruyama, Ilseung Choi, Yoshiko Atsuta, Rika Sakai, Kazuho Miyashita, Yukiyoshi Moriuchi, Hideki Tsujimura, Nobuko Kubota, Go Yamamoto, Tadahiko Igarashi, Koji Izutsu, Shinichiro Yoshida, Kensuke Kojima, Toshiki Uchida, Yoshiko Inoue, Norifumi Tsukamoto, Eiichi Ohtsuka, Sachiko Suzuki, Yoko Inaguma, Satoshi Ichikawa, Hiroshi Gomyo, Yoko Ushijima, Kisato Nosaka, Mio Kurata, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami, Shigeru Kusumoto. Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy. Cancer Science 2021; 112(5): 1943 doi: 10.1111/cas.14846
6
Tianxiang Lei, Fengbo Tan, Zhouhua Hou, Peng Liu, Xianhui Zhao, Heli Liu. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.596500
7
Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack, Tamar Tadmor. The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 2017; 17(12): 863 doi: 10.1016/j.clml.2017.07.008
8
Cara D. Varley, Kevin L. Winthrop. Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Current Rheumatology Reports 2021; 23(9) doi: 10.1007/s11926-021-01037-3
9
Jian Li, Ming Wang, Bo Zhang, Xin Wu, Tian-Long Lin, Xiu-Feng Liu, Ye Zhou, Xin-Hua Zhang, Hao Xu, Li-Jing Shen, Jing Zou, Ping Lu, Dong Zhang, Wei-Jun Gu, Mei-Xia Zhang, Jian Pan, Hui Cao, Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World Journal of Gastroenterology 2018; 24(46): 5189-5202 doi: 10.3748/wjg.v24.i46.5189
10
Carmen Ka Man Cheung, Man Fai Law, David Chun Chao, Sunny Hei Wong, Rita Ho, Amelia Chien Wei Chao, Jennifer Wing Yan Lai, Ted Yun Tat Chan, Mark Tsz Kin Tam, Sam Lik Fung Lau, Tommy Ho Chi Tam. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta‐analysis. Journal of Digestive Diseases 2020; 21(3): 160 doi: 10.1111/1751-2980.12848
11
Ling-Yi Wang, Sung-Chao Chu, Yin Lo, Yen-Yun Yang, K. Arnold Chan. Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan. JAMA Network Open 2021; 4(4): e214132 doi: 10.1001/jamanetworkopen.2021.4132
12
Esma EROĞLU, Cahit YAVUZ. Seroprevalence of HBsAg, Anti-HBs, Anti-HCV and Anti-HIV in Behçet’s Disease. Journal of Contemporary Medicine 2021; 11(5): 690 doi: 10.16899/jcm.912691
13
Wei Huang, Lingyao Du, Hong Tang. Hepatitis B Virus Reactivation: Overview and Management. Future Virology 2021; 16(12): 821 doi: 10.2217/fvl-2021-0275
14
Michelle Spaan, Matthew Bruce, Kosh Agarwal, Ivana Carey. The Role of Anti-HBs in Hepatitis B Reactivation during Direct-Acting Antiviral Therapy for Chronic Hepatitis C. Antiviral Therapy 2018; 23(6): 539 doi: 10.3851/IMP3259
15
Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017; 66(1): 27 doi: 10.1002/hep.29135
16
Lars Kurch, Thomas W. Georgi, Astrid Monecke, Daniel Seehofer, Gudrun Borte, Osama Sabri, Regine Kluge, Simone Heyn, Matthias Pierer, Uwe Platzbecker, Sabine Kayser. Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.798757
17
Jeffrey J. Bruno, Frank P. Tverdek. Oncologic Critical Care. 2020; : 153 doi: 10.1007/978-3-319-74588-6_27
18
Ilkay Bozkurt, Hatun Ozturk Cerik, Seher Kir, Muge Ustaoglu, Mehmet Turgut, Saban Esen. Evaluation of Hepatitis B screening and reactivation in patients receiving rituximab containing chemotherapy: A single‐centre study. International Journal of Clinical Practice 2021; 75(10) doi: 10.1111/ijcp.14685
19
Jie Wang, Junqiao Jia, Ran Chen, Shanlong Ding, Qiang Xu, Ting Zhang, Xiangmei Chen, Shuang Liu, Fengmin Lu. RFX1 participates in doxorubicin‐induced hepatitis B virus reactivation. Cancer Medicine 2018; 7(5): 2021 doi: 10.1002/cam4.1468
20
Alyson Kaplan, Elliott DeHaan, Charles Maltz. Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus. ACG Case Reports Journal 2021; 8(5): e00594 doi: 10.14309/crj.0000000000000594
21
Jeffrey J. Bruno, Frank P. Tverdek. Oncologic Critical Care. 2019; : 1 doi: 10.1007/978-3-319-74698-2_27-2
22
Małgorzata Pawłowska, Robert Flisiak, Lidia Gil, Andrzej Horban, Iwona Hus, Jerzy Jaroszewicz, Ewa Lech-Marańda, Jan Styczyński. Profilaktyka reaktywacji zakażeń HBV – rekomendacje grupy roboczej profilaktyki reaktywacji HBV. Acta Haematologica Polonica 2019; 50(4): 192 doi: 10.2478/ahp-2019-0031
23
Sirish Sanaka, Hans L Tillmann. Article Commentary: Hindsight is 20/20 – the Importance of Knowing! Know your Patients’ HBV Status. Antiviral Therapy 2018; 23(6): 471 doi: 10.3851/IMP3260
24
Prowpanga Udompap, W. Ray Kim. Hepatitis B Virus and Liver Disease. 2021; : 427 doi: 10.1007/978-981-16-3615-8_18
25
Stefano Molica, Luciano Levato, Rosanna Mirabelli, Alessanda Tedeschi, Mirella Lentini. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients. Leukemia & Lymphoma 2018; 59(11): 2734 doi: 10.1080/10428194.2018.1436175
26
Tao Li, Jing Li, Yang Yang, Yilin Han, Dirong Wu, Tao Xiao, Yang Wang, Ting Liu, Yonglong Zhao, Yongjun Li, Zeqin Dai, Xiaozhong Fu. Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBV. Bioorganic & Medicinal Chemistry 2019; 27(16): 3707 doi: 10.1016/j.bmc.2019.07.012
27
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung, Man Fai Law. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World Journal of Gastroenterology 2023; 29(33): 4942-4961 doi: 10.3748/wjg.v29.i33.4942
28
А.В. Чистякова, Н.И. Стуклов, Г.А. Дудина, П.П. Огурцов, Н.В. Мазурчик, А.В. Пивник. Clinical Significance of Chronic Hepatitis C in HIV-infected Patients with Burkitt Lymphoma. Гематология. Трансфузиология. Восточная Европа 2020; (1): 91 doi: 10.34883/PI.2020.6.1.009
29
Malgorzata McMasters, Barbra M. Blair, Hillard M. Lazarus, Carolyn D. Alonso. Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. Blood Reviews 2021; 47: 100779 doi: 10.1016/j.blre.2020.100779
30
José Pedro Carda, Lurdes Santos, José Mário Mariz, Pedro Monteiro, Humberto Miguel Gonçalves, João Raposo, Maria Gomes da Silva. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations. Hematology 2021; 26(1): 785 doi: 10.1080/16078454.2021.1980690
31
Branko Borojevic, Ayushi Chauhan, Scott Patterson. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma. BMJ Case Reports 2021; 14(7): e243526 doi: 10.1136/bcr-2021-243526
32
Chih-An Shih, Wen-Chi Chen. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World Journal of Clinical Cases 2021; 9(21): 5769-5781 doi: 10.12998/wjcc.v9.i21.5769
33
Ling‐Yi Wang, Sung‐Chao Chu, I‐Yun Chang, K. Arnold Chan. Sex‐specific incidence of hepatitis B virus flares among Bcr‐Abl tyrosine kinase inhibitor users in Taiwan. Pharmacoepidemiology and Drug Safety 2023; 32(12): 1368 doi: 10.1002/pds.5667
34
Successful Treatment of HCV/TB co-infected Patient With Sofosbuvir and Daclatasvir: A Case Report. Future Virology 2018; 13(5): 317 doi: 10.2217/fvl-2017-0141
35
Chi-Yu Chen, Tun-Chieh Chen. Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review. Medicine 2024; 103(14): e37653 doi: 10.1097/MD.0000000000037653
36
Laura Ambra Nicolini, Emanuela Zappulo, Claudio Viscoli, Malgorzata Mikulska. Management of chronic viral hepatitis in the hematological patient. Expert Review of Anti-infective Therapy 2018; 16(3): 227 doi: 10.1080/14787210.2018.1438264
37
Elżbieta Halina Kłujszo, Dorota Zarębska‐Michaluk, Beata Kręcisz, Anna Witkowska. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatologic Therapy 2022; 35(3) doi: 10.1111/dth.15274
38
Alessandra Zannella, Massimo Marignani, Paola Begini. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019; 11(9): 858 doi: 10.3390/v11090858
39
Maria Gabriela Fernandes Dezan, Lourianne Nascimento Cavalcante, Helma Pinchemel Cotrim, Andre Castro Lyra. Hepatobiliary disease after bone marrow transplant. Expert Review of Gastroenterology & Hepatology 2023; 17(2): 129 doi: 10.1080/17474124.2023.2169671
40
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2018; 74(9): 1111 doi: 10.1007/s00228-018-2487-4
41
Nina Shah, Jack Aiello, David E Avigan, Jesus G Berdeja, Ivan M Borrello, Ajai Chari, Adam D Cohen, Karthik Ganapathi, Lissa Gray, Damian Green, Amrita Krishnan, Yi Lin, Elisabet Manasanch, Nikhil C Munshi, Ajay K Nooka, Aaron P Rapoport, Eric L Smith, Ravi Vij, Madhav Dhodapkar. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for ImmunoTherapy of Cancer 2020; 8(2): e000734 doi: 10.1136/jitc-2020-000734
42
Yibo Wu, He Huang, Yi Luo. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology 2021; 11 doi: 10.3389/fimmu.2020.610500
43
Matthew Kelling, Lubomir Sokol, Samir Dalia. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. Cancer Control 2018; 25(1): 107327481876787 doi: 10.1177/1073274818767879
44
João Marcello de Araujo-Neto, Gabriela Sousa Guimarães, Flavia Ferreira Fernandes, Marcelo A. Soares. Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective Studies. Viruses 2022; 14(8): 1780 doi: 10.3390/v14081780
45
Anna Korycka-Wołowiec, Dariusz Wołowiec, Tadeusz Robak. The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety 2016; : 1 doi: 10.1080/14740338.2017.1264387
46
Mauro Passucci, Chiara Masucci, Francesca Paoletti, Claudia Ielo, Alessandro Costa, Ida Carmosino, Emilia Scalzulli, Maurizio Martelli, Giuseppe Gentile, Massimo Breccia. Case Report: Infectious prophylaxis in hematological malignancies. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1163175
47
Soe Thiha Maung, Natee Deepan, Pakanat Decharatanachart, Roongruedee Chaiteerakij. Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy – A systematic review and meta‐analysis. Asia-Pacific Journal of Clinical Oncology 2024;  doi: 10.1111/ajco.14055
48
Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan. Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease 2019; 23(3): 487 doi: 10.1016/j.cld.2019.04.009
49
Sebahat Cam, Mustafa Asim Yoruk. Alteration in Hepatitis B Serology in Children Receiving Chemotherapy. Viral Immunology 2020; 33(10): 628 doi: 10.1089/vim.2020.0194
50
Nancy Law, Randy A. Taplitz. How I manage infection risk and prevention in patients with lymphoid cancer. Blood 2022; 139(10): 1517 doi: 10.1182/blood.2019003687
51
María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban, Vincent Wong. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLOS ONE 2017; 12(9): e0184550 doi: 10.1371/journal.pone.0184550
52
Daniel Sedhom, Melroy D’Souza, Elizabeth John, Vinod Rustgi. Viral Hepatitis and Acute Liver Failure. Clinics in Liver Disease 2018; 22(2): 289 doi: 10.1016/j.cld.2018.01.005
53
Adeniyi Abraham Adesola, Matei-Alexandru Cozma, Yong-Feng Chen, Bahadar Singh Srichawla, Mihnea-Alexandru Găman. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World Journal of Hepatology 2023; 15(11): 1188-1195 doi: 10.4254/wjh.v15.i11.1188
54
Prowpanga Udompap, W. Ray Kim. Hepatitis B Virus and Liver Disease. 2018; : 315 doi: 10.1007/978-981-10-4843-2_16
55
Anjula Kumari, Shakuntala Shakuntala, Prakash Jha. A DESCRIPTIVE STUDY TO ASSESS THE KNOWLEDGE AND ATTITUDE OF STAFF NURSES REGARDING PREVENTION OF HEPATITIS –B. GLOBAL JOURNAL FOR RESEARCH ANALYSIS 2022; : 153 doi: 10.36106/gjra/9009072
56
Kazuo Notsumata, Yoshimoto Nomura, Akihiro Tanaka, Yoshikatsu Nomura, Teruyuki Ueda, Taku Sanada, Hiroyuki Watanabe, Daisyu Toya. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study. Internal Medicine 2020; 59(20): 2457 doi: 10.2169/internalmedicine.4445-20
57
Chiara Coluccio, Paola Begini, Alfredo Marzano, Adriano Pellicelli, Barbara Imperatrice, Giulia Anania, Gianfranco Delle Fave, Massimo Marignani. Hepatitis B in patients with hematological diseases: An update. World Journal of Hepatology 2017; 9(25): 1043-1053 doi: 10.4254/wjh.v9.i25.1043
58
Ayşe İnci, Özgür Açıkgöz, Mustafa Uygar Kalaycı, Volkan Ülker. The Positivity Ratios of HBsAg, Anti-HBs and Isolated Anti-HBc in Patients with Breast and Gynecologic Cancers Prior to Chemotherapy. Journal of Clinical and Experimental Investigations 2018; 9(2) doi: 10.5799/jcei.433817
59
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy era. Expert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
60
Takako Inoue, Takeshi Matsui, Yasuhito Tanaka. Novel strategies for the early diagnosis of hepatitis B virus reactivation. Hepatology Research 2021; 51(10): 1033 doi: 10.1111/hepr.13699
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345